AU2016258952C1 - Proteins specific for CD137 - Google Patents
Proteins specific for CD137 Download PDFInfo
- Publication number
- AU2016258952C1 AU2016258952C1 AU2016258952A AU2016258952A AU2016258952C1 AU 2016258952 C1 AU2016258952 C1 AU 2016258952C1 AU 2016258952 A AU2016258952 A AU 2016258952A AU 2016258952 A AU2016258952 A AU 2016258952A AU 2016258952 C1 AU2016258952 C1 AU 2016258952C1
- Authority
- AU
- Australia
- Prior art keywords
- ser
- lys
- asp
- leu
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166184.0 | 2015-05-04 | ||
| EP15166184 | 2015-05-04 | ||
| PCT/EP2016/059959 WO2016177762A1 (en) | 2015-05-04 | 2016-05-04 | Proteins specific for cd137 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2016258952A1 AU2016258952A1 (en) | 2017-11-09 |
| AU2016258952B2 AU2016258952B2 (en) | 2020-08-27 |
| AU2016258952C1 true AU2016258952C1 (en) | 2020-12-24 |
Family
ID=53054879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016258952A Active AU2016258952C1 (en) | 2015-05-04 | 2016-05-04 | Proteins specific for CD137 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11261221B2 (enExample) |
| EP (2) | EP4177262A1 (enExample) |
| JP (3) | JP6884708B2 (enExample) |
| KR (1) | KR102734408B1 (enExample) |
| CN (2) | CN114573680A (enExample) |
| AU (1) | AU2016258952C1 (enExample) |
| CA (1) | CA2980839C (enExample) |
| CL (1) | CL2017002767A1 (enExample) |
| DK (1) | DK3292137T3 (enExample) |
| ES (1) | ES2932425T3 (enExample) |
| IL (1) | IL254516B (enExample) |
| MX (1) | MX2017014082A (enExample) |
| NZ (1) | NZ736560A (enExample) |
| PH (1) | PH12017501583B1 (enExample) |
| RU (1) | RU2736312C2 (enExample) |
| SG (1) | SG11201708339QA (enExample) |
| WO (1) | WO2016177762A1 (enExample) |
| ZA (1) | ZA201705960B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2564125C2 (ru) | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| CA2891557A1 (en) | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| SG10201912019WA (en) | 2014-05-22 | 2020-02-27 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| CA2973640A1 (en) | 2015-01-28 | 2016-08-04 | Rachida Siham Bel Aiba | Novel proteins specific for angiogenesis |
| EP4177262A1 (en) | 2015-05-04 | 2023-05-10 | Pieris Pharmaceuticals GmbH | Proteins specific for cd137 |
| EP3292148B1 (en) | 2015-05-04 | 2024-01-24 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| JP6947642B2 (ja) | 2015-05-18 | 2021-10-13 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん性融合ポリペプチド |
| RU2756318C2 (ru) | 2015-05-18 | 2021-09-29 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) |
| SG10201911499TA (en) | 2015-11-30 | 2020-01-30 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| US12285410B2 (en) | 2018-03-26 | 2025-04-29 | 4Sc Ag | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy |
| JP7651450B2 (ja) | 2018-07-24 | 2025-03-26 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法 |
| AU2019315703A1 (en) * | 2018-07-31 | 2020-12-10 | Les Laboratoires Servier | Novel fusion protein specific for CD137 and PD-L1 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| CA3115285A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| EP3931209A1 (en) * | 2019-02-26 | 2022-01-05 | Pieris Pharmaceuticals GmbH | Novel fusion proteins specific for cd137 and gpc3 |
| CN113939307A (zh) | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| EP3952996A1 (en) | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
| KR20220097952A (ko) | 2019-11-04 | 2022-07-08 | 피어이스 파마슈티컬즈 게엠베하 | 암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질 |
| CA3177098A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| US20230366884A1 (en) | 2020-09-18 | 2023-11-16 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
| WO2022200412A2 (en) | 2021-03-23 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
| WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| EP4590695A1 (en) | 2022-09-21 | 2025-07-30 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029463A2 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| JPH10500672A (ja) | 1994-05-18 | 1998-01-20 | インヘイル セラピューティック システムズ，インコーポレイティド | インターフェロンの乾燥粉末製剤に関する方法及び組成物 |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| HRP20000808A2 (en) | 1998-06-08 | 2001-10-31 | Hoffmann La Roche | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| DK2046820T3 (da) | 2006-08-01 | 2011-02-07 | Pieris Ag | Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf |
| WO2009052392A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CA2729322C (en) | 2008-06-24 | 2020-05-26 | Technische Universitaet Muenchen | Muteins of hngal and related proteins with affinity for a given target |
| RU2564125C2 (ru) * | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| DK2606061T3 (da) * | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| CA2905186A1 (en) | 2013-03-14 | 2014-09-18 | Daiichi Sankyo Co., Ltd | Novel binding proteins for pcsk9 |
| CA2891557A1 (en) * | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CA2973640A1 (en) | 2015-01-28 | 2016-08-04 | Rachida Siham Bel Aiba | Novel proteins specific for angiogenesis |
| WO2016131804A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| EP4177262A1 (en) | 2015-05-04 | 2023-05-10 | Pieris Pharmaceuticals GmbH | Proteins specific for cd137 |
| EP3292148B1 (en) | 2015-05-04 | 2024-01-24 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| JP6947642B2 (ja) * | 2015-05-18 | 2021-10-13 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん性融合ポリペプチド |
| RU2756318C2 (ru) | 2015-05-18 | 2021-09-29 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
-
2016
- 2016-05-04 EP EP22193830.1A patent/EP4177262A1/en active Pending
- 2016-05-04 RU RU2017135599A patent/RU2736312C2/ru active
- 2016-05-04 WO PCT/EP2016/059959 patent/WO2016177762A1/en not_active Ceased
- 2016-05-04 US US15/571,611 patent/US11261221B2/en active Active
- 2016-05-04 AU AU2016258952A patent/AU2016258952C1/en active Active
- 2016-05-04 SG SG11201708339QA patent/SG11201708339QA/en unknown
- 2016-05-04 CN CN202210118268.XA patent/CN114573680A/zh active Pending
- 2016-05-04 MX MX2017014082A patent/MX2017014082A/es unknown
- 2016-05-04 PH PH1/2017/501583A patent/PH12017501583B1/en unknown
- 2016-05-04 DK DK16721149.9T patent/DK3292137T3/da active
- 2016-05-04 JP JP2017557299A patent/JP6884708B2/ja active Active
- 2016-05-04 NZ NZ736560A patent/NZ736560A/en unknown
- 2016-05-04 KR KR1020177034948A patent/KR102734408B1/ko active Active
- 2016-05-04 EP EP16721149.9A patent/EP3292137B1/en active Active
- 2016-05-04 CA CA2980839A patent/CA2980839C/en active Active
- 2016-05-04 CN CN201680025274.3A patent/CN107820500B/zh active Active
- 2016-05-04 ES ES16721149T patent/ES2932425T3/es active Active
-
2017
- 2017-09-01 ZA ZA2017/05960A patent/ZA201705960B/en unknown
- 2017-09-14 IL IL254516A patent/IL254516B/en unknown
- 2017-11-02 CL CL2017002767A patent/CL2017002767A1/es unknown
-
2021
- 2021-03-09 JP JP2021036823A patent/JP7149363B2/ja active Active
-
2022
- 2022-01-19 US US17/579,392 patent/US12195503B2/en active Active
- 2022-09-26 JP JP2022152103A patent/JP7477905B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029463A2 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12195503B2 (en) | Proteins specific for CD137 | |
| AU2016293101B2 (en) | Novel proteins specific for LAG-3 | |
| US11773147B2 (en) | Lipocalin muteins with binding affinity for LAG-3 | |
| WO2018087108A1 (en) | Proteins specific for cd137 | |
| HK40093181A (en) | Proteins specific for cd137 | |
| HK1249527B (en) | Proteins specific for cd137 | |
| BR112017020426B1 (pt) | Muteína de lipocalina, uso de uma ou mais muteínas e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 SEP 2020 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 SEP 2020 |
|
| FGA | Letters patent sealed or granted (standard patent) |